Dr. Alexander "Sandro" Sulakvelidze, Ph.D., is the President and CEO of Intralytix, Inc. Dr. Sulakvelidze is an internationally recognized expert in phage technology. He has published extensively about phage biocontrol and phage therapy and has pioneered the approach of using bacteriophages for modulating human microbiome. Dr. Sulakvelidze served as founding Editor-in-Chief of the journal Bacteriophage. He also co-edited a major book about bacteriophages called "Bacteriophages: Biology and Applications," which was published by the CRC Press. Dr. Sulakvelidze serves on numerous review panels for various scientific journals and funding agencies, and he is also the author of several issued and pending patents in the field of bacteriophages. Since the inception of the Company, Dr. Sulakvelidze has been leading all product development and commercialization efforts and he has been directly responsible for shaping up all operational priorities.

Gary Pasternack is former Director of the Division of Molecular Pathology and of the Graduate Program in Pathobiology at the Johns Hopkins University School of Medicine. He received his undergraduate, MD, and PhD degrees from Johns Hopkins and did his residency and fellowship training at Yale.

Dr. Pasternack is or has been a principal in a number of biotechnology businesses, is an inventor on over ten issued U.S. patents, and consults actively in the biotechnology, pharmaceutical, and financial communities.

Dr. Pasternack currently serves as the CEO of Asklepion Pharmaceuticals, LLC., a biopharmaceutical company based in Baltimore, Maryland.

Mr. Hervy is an entrepreneur and experienced CEO of small to large corporations. Following his MBA from the Wharton School, University of Pennsylvania, in 1974, he joined Thomson, SA, an international industrial group and became, until 1984, the President and CEO of Thomson CGR Medical Corporation, a medical imaging company with sales of over $100 million and 1,300 employees.

In 1985, Mr. Hervy acquired Sopha Medical Systems, Inc., a nuclear medicine company. As Sopha's Chairman and CEO, as well as its entrepreneur and principal owner, Mr. Hervy executed a successful turn around and growth plan by the time he sold it in 1988.

As part of his community involvement, Mr. Hervy also served as a founding trustee of the Maryland Venture Capital Trust, as chairman of MDBio, Inc., and as a trustee of St. Mary's College of Maryland and of the Wildfowl Trust of North America.

Brice-Audren Riché - Mr. Riché is the CEO of Lesaffre, a global key player in yeasts and fermentation with over 10,500 employees worldwide. A graduate of the Ecole Polytechnique, Mr. Riché began his career with Ernst & Young in 1997. In 2001 he joined Lafarge and held various finance positions in Europe, Asia, and Latin America. Mr. Riché joined Lesaffre in 2017 as Global General Manager of Biospringer; he has been appointed as the CEO of Lesaffre in January 2022.

Jon Kully is the co-founder and managing partner of Flank - a vertically integrated real-estate development firm in New York. He has completed over $1b in projects and has $700M presently under construction. Jon raised a private equity fund in 2018. His practice is focused on delivering best in class product and returning outsized returns to investors. Jon sits on the board of advisors for the Dean of Columbia's GSAPP. He resides in the West Village with his wife and two children.